Revenue from Contract with Customer, Excluding Assessed Tax of Spyre Therapeutics, Inc. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Spyre Therapeutics, Inc. annual and quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • Spyre Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 31 Dec 2024 was $0.
  • Spyre Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 31 Dec 2024 was $0, a 100% decline year-over-year.
  • Spyre Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2025 was $0.
  • Spyre Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $0, a 100% decline from 2023.
  • Spyre Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $886,000, a 62% decline from 2022.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $0 $0 01 Jan 2025 31 Dec 2025 10-K 19 Feb 2026 2025 FY
2024 $0 -$886,000 -100% 01 Jan 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
2023 $886,000 -$1,443,000 -62% 01 Jan 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
2022 $2,329,000 -$16,410,000 -88% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $18,739,000 +$18,739,000 01 Jan 2021 31 Dec 2021 10-K/A 18 Nov 2024 2023 FY
2020 $0 $0 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $0 -$3,888,000 -100% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
2018 $3,888,000 -$1,317,000 -25% 01 Jan 2018 31 Dec 2018 10-K 18 Mar 2021 2020 FY
2017 $5,205,000 +$577,000 +12% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
2016 $4,628,000 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY

Spyre Therapeutics, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $0 $0 $0 01 Oct 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
Q3 2024 $0 $0 $0 01 Jul 2024 30 Sep 2024 10-Q/A 18 Nov 2024 2024 Q3
Q2 2024 $0 $0 -$688,000 -100% 01 Apr 2024 30 Jun 2024 10-Q/A 18 Nov 2024 2024 Q2
Q1 2024 $688,000 $0 -$198,000 -100% 01 Jan 2024 31 Mar 2024 10-Q/A 18 Nov 2024 2024 Q1
Q4 2023 $886,000 $0 -$168,000 -100% 01 Oct 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
Q3 2023 $1,054,000 $0 -$174,000 -100% 01 Jul 2023 30 Sep 2023 10-Q/A 18 Nov 2024 2024 Q3
Q2 2023 $1,228,000 $688,000 +$63,000 +10% 01 Apr 2023 30 Jun 2023 10-Q/A 18 Nov 2024 2024 Q2
Q1 2023 $1,165,000 $198,000 -$1,164,000 -85% 01 Jan 2023 31 Mar 2023 10-Q/A 18 Nov 2024 2024 Q1
Q4 2022 $2,329,000 $168,000 -$3,476,000 -95% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $5,805,000 $174,000 -$1,225,000 -88% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,030,000 $625,000 -$13,071,000 -95% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $20,101,000 $1,362,000 +$1,362,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $18,739,000 $3,644,000 01 Oct 2021 31 Dec 2021 10-K/A 18 Nov 2024 2023 FY
Q3 2021 $1,399,000 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $13,696,000 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $0 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q1 2019 $2,378,000 $0 -$1,510,000 -100% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 $3,888,000 $0 -$1,483,000 -100% 01 Oct 2018 31 Dec 2018 10-K 07 Mar 2019 2018 FY
Q3 2018 $5,371,000 $0 -$1,261,000 -100% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $6,632,000 $2,378,000 +$899,000 +61% 01 Apr 2018 30 Jun 2018 10-K 24 Feb 2020 2019 FY
Q1 2018 $5,733,000 $1,510,000 +$528,000 +54% 01 Jan 2018 31 Mar 2018 10-K 24 Feb 2020 2019 FY
Q4 2017 $5,205,000 $1,483,000 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 $1,261,000 01 Jul 2017 30 Sep 2017 10-K 07 Mar 2019 2018 FY
Q2 2017 $1,479,000 01 Apr 2017 30 Jun 2017 10-K 07 Mar 2019 2018 FY
Q1 2017 $982,000 01 Jan 2017 31 Mar 2017 10-K 07 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.